- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04443374
The Turkish Version of the Simple Physical Activity Questionnaire (SIMPAQ) (SIMPAQ)
The Reliability and Validity of the Turkish Version of the Simple Physical Activity Questionnaire (SIMPAQ)
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey, 34500
- Istanbul University-Cerrahpasa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Aged between 18 and 60 years Being a volunteer to participate Being an outpatient or inpatient at the place of the study Being diagnosed with major depression, bipolar disorder, anxiety disorder, schizophrenia, alcohol and substance addiction according to DSM-5 or ICD.
Exclusion Criteria:
Having cognitive impairment Having disabilities in understanding, speaking and reading Turkish Having vision and / or hearing problems
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Simple Physical Activity Questionnaire
Time Frame: Baseline (First assessment)
|
The SIMPAQ is a reliable and valid tool to assess physical activity in people with mental illness.
The 5-item SIMPAQ was designed to capture activity over a representative 24-h period from the previous 7-days.
Time spent in bed overnight, time sedentary, including napping, time spent walking, time spent exercising and time engaged in incidental activity are questioned and the sum of them should be approximately 24 h.
This structure of the SIMPAQ provides interviewers to understand under or over-reporting.
For an estimate of total self-reported moderate-vigorous physical activity (MVPA) time, time spent walking and exercising were combined to provide total MVPA (hours per week).
|
Baseline (First assessment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Simple Physical Activity Questionnaire
Time Frame: Within a 5-to-7-day period after the first assessment (Second assessment)
|
The SIMPAQ is a reliable and valid tool to assess physical activity in people with mental illness.
The 5-item SIMPAQ was designed to capture activity over a representative 24-h period from the previous 7-days.
Time spent in bed overnight, time sedentary, including napping, time spent walking, time spent exercising and time engaged in incidental activity are questioned and the sum of them should be approximately 24 h.
This structure of the SIMPAQ provides interviewers to understand under or over-reporting.
For an estimate of total self-reported moderate-vigorous physical activity (MVPA) time, time spent walking and exercising were combined to provide total MVPA (hours per week).
|
Within a 5-to-7-day period after the first assessment (Second assessment)
|
International Physical Activity Questionnaire-Short Form
Time Frame: Baseline (First assessment)
|
International Physical Activity Questionnaire-Short Form (IPAQ-SF) is a self-report questionnaire that assesses PA in the last 7 days.
IPAQ-SF provides information on walking, moderate and vigorous activities and time spent sitting, within a week.
|
Baseline (First assessment)
|
Brief Psychiatric Rating Scale
Time Frame: Baseline (First assessment)
|
Brief Psychiatric Rating Scale (BPRS) is a valid 18-item quantitative scale for assessing psychopathology and its severity.
Each item is measured on a five-point scale (0 = none to 4 = very severe), with lower scores meaning a lower severity of the symptom.
|
Baseline (First assessment)
|
DSM-5 Level 1 Cross-Cutting Symptom Measure-Adult
Time Frame: Baseline (First assessment)
|
DSM-5 Level 1 Cross-Cutting Symptom Measure-Adult (DSM XC) comprises 23 self-rated symptoms that capture 13 mental health domains.
Respondents indicate how much (or how often) they have been bothered by each symptom in the prior two weeks using a five-point response scale (none, not at all to severe, nearly every day).
A score of 2 or higher in most domains, except substance use (score of 1 or higher) is suggestive of clinically-relevant mental health problems.
|
Baseline (First assessment)
|
Collaborators and Investigators
Investigators
- Study Director: Ebru KAYA MUTLU, PT, PhD, Istanbul University-Cerrahpasa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychiatric Disorder
-
Mental Health Services in the Capital Region, DenmarkUniversity of CopenhagenRecruitingMental Illness | Behavior Disorders | Psychiatric Disorder | Mental Disorder | Severe Mental Disorder | Psychiatric Illness | Diagnosis, Psychiatric | Psychiatric Disease | Diagnosis DualDenmark
-
University of Lausanne HospitalsNot yet recruitingPsychiatric Disorder | Involuntary Psychiatric HospitalizationSwitzerland
-
The Miriam HospitalCompletedTobacco Smoking | Psychiatric Disorder | Psychiatric HospitalizationUnited States
-
Uppsala UniversityTerminatedPsychosis | Psychiatric Disorder | Psychiatric Hospitalization | Compulsory Psychiatric Care Act | Acceptance & Commitment TherapySweden
-
Brigham and Women's HospitalRecruitingDepression | Mood Disorders | Depressive Disorder, Major | Psychiatric Disorder | Mental DisorderUnited States
-
Brigham and Women's HospitalNot yet recruitingAnxiety Disorders | Psychiatric Disorder | Mental DisorderUnited States
-
Hospices Civils de LyonRecruitingNeurologic Disorder | Psychiatric DisorderFrance
-
Medical University of ViennaRecruitingObsessive-Compulsive Disorder | Psychiatric DisorderAustria
-
Mostafa BahaaMostafa Mahmoud Bahaa Clinical Pharmacy Department, Horus University, New...Not yet recruitingPsychiatric Disorder
-
Vrije Universiteit BrusselNot yet recruiting